Compare Invesco DB Commodity Index Tracking Fund (DBC) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Commodity Index Tracking Fund vs Summit Therapeutics Inc — how do they compare? Invesco DB Commodity Index Tracking Fund trades at $28.98, while Summit Therapeutics Inc trades at $15.55 (market cap $12.01B). The key difference: Invesco DB Commodity Index Tracking Fund is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| DBC | SMMT | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $31.69 | $29.32 |
52-Week Low | $21.62 | $13.05 |
Market Cap | — | $12.01B |
Enterprise Value | — | $11.43B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBC, the Invesco DB Commodity Index Tracking ETF, trades at $28.33, up 2.94% today, with a bullish technical signal from moving averages and oscillators. Recent news highlights its role as an inflation hedge, with a 52-week high noted in April 2026. The ETF provides diversified commodity exposure, benefiting from oil supply shocks and safe-haven demand, though key financial ratios like P/E and P/S are not applicable for this fund structure.
Outlook remains positive due to strong momentum and inflation hedging appeal, but risks include commodity price volatility and geopolitical factors. Analyst sentiment is supportive, with the ETF favored in balanced portfolios for moderate-risk investors seeking commodity diversification amid market uncertainty.
Summit Therapeutics (SMMT) trades at $15.30, showing modest daily gains of 0.33%. The stock faces bearish technical signals with negative cash flows and substantial losses (-$1.08B net income in 2025). Recent developments include the sale of Phase III asset ridinilazole and positive clinical trial results for ivonescimab. Analyst sentiment remains optimistic with 67% buy ratings and a $15.57 consensus target, though financial metrics show concerning profitability with -270.95% ROE.
SMMT presents a high-risk, catalyst-driven opportunity with binary outcomes dependent on clinical success. The company's heavy reliance on ivonescimab development creates significant upside potential but also substantial execution risk. Negative cash flow trends and persistent losses require careful monitoring of upcoming Q2 2026 earnings and clinical milestones for directional clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Invesco DB Commodity Index Tracking Fund
DBC is a diversified commodity ETF that tracks the DBIQ Optimum Yield Diversified Commodity Index. It invests in futures contracts for 14 heavily traded commodities, including crude oil, gold, and corn, while optimizing for yield and roll costs.
Read more on DBC →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
